MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cardfail.2023.11.016

Медицинская библиотека · Journal of cardiac failure · 2023

Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.

Masri Ahmad, Maurer Mathew S, Claggett Brian L, Kulac Ian, Waddington Cruz Marcia, Conceição Isabel, Weiler Markus, Berk John L, Gertz Morie, Gillmore Julian D, Rush Stephen, Chen Jersey, Zhou Wunan, Kwoh Jesse, Duran Jason M, Tsimikas Sotirios, Solomon Scott D

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Hereditary transthyretin amyloidosis (ATTRv) is associated with polyneuropathy, cardiomyopathy, or both. The effects of eplontersen on cardiac structure and function were assessed.

METHODS AND

RESULTS

NEURO-TTRansform was an open-label trial involving 144 adults with ATTRv polyneuropathy (49 patients [34%] with cardiomyopathy) receiving eplontersen throughout and compared with a historical placebo group (n = 60; 30 patients [50%] with cardiomyopathy) from the NEURO-TTR trial at week 65. Treatment effect (eplontersen vs placebo), presented as mean difference (95% confidence interval) was analyzed after adjusting for age, sex, region, baseline value, ATTRv disease stage, previous ATTRv treatment, and V30M transthyretin variant. There were notable differences at baseline between the eplontersen group and historical placebo. In the cardiomyopathy subgroup, 65 weeks of eplontersen treatment was associated with improvement from baseline relative to placebo in left ventricular ejection fraction of 4.3% (95% confidence interval 1.40-21.01; P = .049) and stroke volume 10.64 mL (95% confidence interval 3.99-17.29; P = .002) while the remainder of echocardiographic parameters remained stable.

CONCLUSIONS

Eplontersen was associated with stable or improved measures of cardiac structure and function vs historical placebo in patients with ATTRv polyneuropathy and cardiomyopathy. Further investigation into eplontersen's effect on transthyretin amyloid cardiomyopathy is being conducted in the CARDIO-TTRansform trial.

Для цитирования: Masri Ahmad, Maurer Mathew S, Claggett Brian L, Kulac Ian, Waddington Cruz Marcia, Conceição Isabel, Weiler Markus, Berk John L, Gertz Morie, Gillmore Julian D, Rush Stephen, Chen Jersey, Zhou Wunan, Kwoh Jesse, Duran Jason M, Tsimikas Sotirios, Solomon Scott D. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.. Journal of cardiac failure. 2023. DOI: 10.1016/j.cardfail.2023.11.016.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.